Gut microbiome stories

Jul 25, 2026

Engineered probiotic bacteria show promise in boosting immune response against pancreatic cancer

Researchers have developed engineered probiotic bacteria designed to overcome the 'cold' tumor microenvironment in pancreatic cancer, potentially enhancing the effectiveness of immunotherapy treatments for this difficult-to-treat disease.

Jul 25, 20261 source

Top claims

▪Pancreatic cancer is difficult to treat because pancreatic tumors often create a cold tumor microenvironment that prevents immune cells from mounting a strong attack.
▪BifidoSumIL-2 is designed to release SumIL-2, an engineered version of interleukin-2, to selectively stimulate cancer-fighting T cells while limiting the activation of regulatory T cells.
▪BifidoSumIL-2 has not yet been tested in humans, requiring future studies to evaluate long-term safety, durability of the immune response, and oral delivery feasibility.

Subtopics

Cancer immunotherapy1 Drug Approval and Clinical Trials1 Interleukin-21 Lifestyle, Wellness and Nutrition1 Pancreatic cancer1 Probiotic bacteria1 Probiotics1 Synthetic biology1

Related timelines